Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $3.10 and last traded at $3.23, with a volume of 56600 shares trading hands. The stock had previously closed at $3.25.
Several brokerages recently weighed in on NVLN. Zacks Investment Research lowered Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. Royal Bank of Canada decreased their price objective on Novelion Therapeutics from $9.00 to $8.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. Finally, ValuEngine lowered Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 12th.
The firm has a market cap of $58.20, a price-to-earnings ratio of -0.45 and a beta of 0.29. The company has a debt-to-equity ratio of 6.53, a current ratio of 1.45 and a quick ratio of 1.28.
TRADEMARK VIOLATION NOTICE: “Novelion Therapeutics (NVLN) Hits New 12-Month Low at $3.10” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/31/novelion-therapeutics-nvln-hits-new-12-month-low-at-3-10.html.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.